-+ 0.00%
-+ 0.00%
-+ 0.00%

Neuphoria Therapeutics 13D Filing Shows Lynx1 Capital Management LP Boosts Stake To 16.3% And Submits Revised $4.75-Per-Share Buyout Proposal For Neuphoria Therapeutics

Benzinga·12/02/2025 13:40:37
Listen to the news

- SEC Filing